AC Immune Stock

AC Immune ROCE 2024

AC Immune ROCE

-0.33

Ticker

ACIU

ISIN

CH0329023102

WKN

A2AR5F

In 2024, AC Immune's return on capital employed (ROCE) was -0.33, a -20.32% increase from the -0.42 ROCE in the previous year.

AC Immune Aktienanalyse

What does AC Immune do?

AC Immune SA is a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of neurodegenerative diseases as well as cancer. It was founded in 2003 by a group of leading researchers in the field of neurodegeneration and is based in Lausanne, Switzerland. The company has established itself as one of the leading companies in Alzheimer's research in recent years. AC Immune SA focuses on developing drugs targeting protein aggregation that occurs in Alzheimer's and other neurodegenerative diseases in the brain. It has developed an innovative platform technology that allows for the development of specific antibodies that selectively bind to certain toxic or disease-causing proteins. AC Immune has developed a variety of proprietary technologies and platforms that enable rapid and efficient identification, testing, and optimization of therapeutics. Its main products are antibodies that therapeutically target Alzheimer's, Parkinson's, TAU, and Alpha-Synuclein prions. These antibodies that target protein disease-related plaques help slow disease progression and alleviate symptoms. AC Immune has also developed and tested drugs for cancer treatment. The company operates in two main segments: research and development, as well as clinical studies. It has a strong pipeline of products in development that are in various stages of clinical trials. These products target various diseases including Alzheimer's, Parkinson's, advanced stage cancer, prion diseases, neurodegenerative sanatoria, and Down syndrome. AC Immune SA collaborates closely with various academic research institutions, biotechnology companies, pharmaceutical companies, and government agencies to bring innovative therapies to market. It has formed numerous partnerships and alliances with renowned partners in the pharmaceutical, biotech, and life science industries to accelerate the translation of promising therapeutic approaches into clinical applications. Recently, AC Immune SA announced a partnership with Genentech, a leading company in the development of biological therapies and diagnostic procedures. The two companies are working together to develop treatments for Alzheimer's and several other neurodegenerative diseases. Another example is the collaboration with Eli Lilly and Company for the use of ACI-3024 in the fight against tauopathies, including Alzheimer's disease and progressive supranuclear palsy. AC Immune SA has a strong foundation in scientific research and development, as well as in the commercialization of therapeutics. The company has a comprehensive product pipeline aimed at developing innovative therapy options for patients with neurodegenerative diseases and cancer. With its proprietary technology platform and partnerships with leading companies in the biotech and pharmaceutical industries, AC Immune SA has great potential to make significant advances in the development of therapies that improve patients' lives and enhance their quality of life. AC Immune ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling AC Immune's Return on Capital Employed (ROCE)

AC Immune's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing AC Immune's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

AC Immune's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in AC Immune’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about AC Immune stock

What is the ROCE (Return on Capital Employed) of AC Immune this year?

The ROCE of AC Immune is -0.33 undefined this year.

How has the ROCE (Return on Capital Employed) of AC Immune developed compared to the previous year?

The ROCE of AC Immune has increased by -20.32% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of AC Immune?

A high Return on Capital Employed (ROCE) indicates that AC Immune has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of AC Immune?

A low ROCE (Return on Capital Employed) can indicate that AC Immune has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from AC Immune impact the company?

An increase in the ROCE of AC Immune can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of AC Immune affect the company?

A decrease in ROCE of AC Immune can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of AC Immune?

Some factors that can affect AC Immune's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of AC Immune so important for investors?

The ROCE of AC Immune is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can AC Immune take to improve the ROCE?

To improve the ROCE, AC Immune can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does AC Immune pay?

Over the past 12 months, AC Immune paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AC Immune is expected to pay a dividend of 0 CHF.

What is the dividend yield of AC Immune?

The current dividend yield of AC Immune is .

When does AC Immune pay dividends?

AC Immune pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AC Immune?

AC Immune paid dividends every year for the past 0 years.

What is the dividend of AC Immune?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is AC Immune located?

AC Immune is assigned to the 'Health' sector.

Wann musste ich die Aktien von AC Immune kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AC Immune from 12/3/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 12/3/2024.

When did AC Immune pay the last dividend?

The last dividend was paid out on 12/3/2024.

What was the dividend of AC Immune in the year 2023?

In the year 2023, AC Immune distributed 0 CHF as dividends.

In which currency does AC Immune pay out the dividend?

The dividends of AC Immune are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von AC Immune

Our stock analysis for AC Immune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AC Immune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.